| Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections SCJ Jorgensen, TD Trinh, EJ Zasowski, AM Lagnf, S Bhatia, SM Melvin, ... Open forum infectious diseases 6 (12), ofz522, 2019 | 118 | 2019 |
| Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections EJ Zasowski, KC Claeys, AM Lagnf, SL Davis, MJ Rybak Clinical Infectious Diseases 62 (10), 1242-1250, 2016 | 116 | 2016 |
| Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections EJ Zasowski, TD Trinh, KC Claeys, AM Casapao, N Sabagha, AM Lagnf, ... Antimicrobial agents and chemotherapy 61 (2), 10.1128/aac. 02015-16, 2017 | 80 | 2017 |
| Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study SCJ Jorgensen, EJ Zasowski, TD Trinh, AM Lagnf, S Bhatia, N Sabagha, ... Clinical Infectious Diseases 71 (1), 1-10, 2020 | 79 | 2020 |
| Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections KC Claeys, EJ Zasowski, AM Casapao, AM Lagnf, JL Nagel, CT Nguyen, ... Antimicrobial agents and chemotherapy 60 (10), 5841-5848, 2016 | 72 | 2016 |
| Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections SCJ Jorgensen, TD Trinh, EJ Zasowski, AM Lagnf, SP Simon, S Bhatia, ... Antimicrobial agents and chemotherapy 64 (4), 10.1128/aac. 02291-19, 2020 | 47 | 2020 |
| Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections S Alosaimy, SCJ Jorgensen, AM Lagnf, S Melvin, RP Mynatt, TJ Carlson, ... Open Forum Infectious Diseases 7 (3), ofaa051, 2020 | 45 | 2020 |
| Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections T Morrisette, S Alosaimy, JV Philley, C Wadle, C Howard, AJ Webb, ... Open Forum Infectious Diseases 8 (2), ofab002, 2021 | 42 | 2021 |
| Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: prevalence and risk factors TD Trinh, EJ Zasowski, KC Claeys, AM Lagnf, S Kidambi, SL Davis, ... Diagnostic microbiology and infectious disease 89 (1), 61-66, 2017 | 41 | 2017 |
| Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa S Alosaimy, AM Lagnf, T Morrisette, MR Scipione, JJ Zhao, ... Open forum infectious diseases 8 (8), ofab371, 2021 | 40 | 2021 |
| Pneumonia caused by methicillin-resistant Staphylococcus aureus: does vancomycin heteroresistance matter? KC Claeys, AM Lagnf, JA Hallesy, MT Compton, AL Gravelin, SL Davis, ... Antimicrobial agents and chemotherapy 60 (3), 1708-1716, 2016 | 38 | 2016 |
| Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer SCJ Jorgensen, AM Lagnf, S Bhatia, MD Shamim, MJ Rybak Journal of Antimicrobial Chemotherapy 74 (2), 489-498, 2019 | 36 | 2019 |
| Early experience with eravacycline for complicated infections S Alosaimy, KC Molina, KC Claeys, J Andrade, J Truong, MA King, ... Open Forum Infectious Diseases 7 (5), ofaa071, 2020 | 34 | 2020 |
| A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections SCJ Jorgensen, KP Murray, AM Lagnf, S Melvin, S Bhatia, MD Shamim, ... Infectious diseases and therapy 9, 89-106, 2020 | 29 | 2020 |
| Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant … AM Casapao, SL Davis, JP McRoberts, AM Lagnf, S Patel, R Kullar, ... Antimicrobial agents and chemotherapy 58 (8), 4636-4641, 2014 | 26 | 2014 |
| Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 24 | 2021 |
| Antimicrobial stewardship opportunities in critically ill patients with gram-negative lower respiratory tract infections: a multicenter cross-sectional analysis KC Claeys, EJ Zasowski, TD Trinh, AM Lagnf, SL Davis, MJ Rybak Infectious diseases and therapy 7, 135-146, 2018 | 24 | 2018 |
| Acute bacterial skin and skin structure infections treated with intravenous antibiotics in the emergency department or observational unit: experience at the Detroit Medical Center KC Claeys, AM Lagnf, TB Patel, MG Jacob, SL Davis, MJ Rybak Infectious diseases and therapy 4, 173-186, 2015 | 24 | 2015 |
| Monotherapy with vancomycin or daptomycin versus combination therapy with β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a … S Alosaimy, NL Sabagha, AM Lagnf, EJ Zasowski, T Morrisette, ... Infectious Diseases and Therapy 9, 325-339, 2020 | 23 | 2020 |
| Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections KC Claeys, EJ Zasowski, AM Lagnf, DP Levine, SL Davis, MJ Rybak International journal of antimicrobial agents 51 (1), 43-46, 2018 | 19 | 2018 |
Kimberly C. ClaeysAssociate Professor University of Maryland School of Pharmacy在 rx.umaryland.edu 的电子邮件经过验证
